Main Conference Day 3 - Europe/Amsterdam
Main Conference Day 3 - Europe/Amsterdam
06:30 - 07:0030 mins
Morning Spotlight Presentation
Fun Run
07:00 - 07:3030 mins
Morning Spotlight Presentation
Registration and Coffee
07:30 - 08:0030 mins
Morning Spotlight Presentation
Advancing TIDES with Flow Chemistry
- Lin Chen, PhD - Associate Vice President, Peptide Manufacturing Technology and R&D, Asymchem
08:00 - 08:055 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairpersons Remarks: Targeted Delivery of Oligonucleotides
08:00 - 08:055 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairwoman's Remarks: Innovations in Oligonucleotide CMC
- Sonja Merkas, PhD - Founder and CEO, Livinovea
08:00 - 08:055 mins
Peptide Discovery to CMC
Chairman’s Remarks: Innovations in Peptide CMC
- Riccardo Bernasconi, Ph.D. - Director Business Development, Bachem
08:05 - 08:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Organ Specific Delivery of Oligonucleotides Using Nanofitins
- Mathieu Cinier - Chief Scientific Officer, Affilogic
08:05 - 08:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Strategies for Implementing a Comprehensive Impurity Control Approach Across Oligonucleotide Purification Process
- Armin Delavari, PhD - Senior Scientist, ASO Purification Process Development, Biogen
08:05 - 08:3530 mins
Peptide Discovery to CMC
High-throughput Synthesis and Screening of > 80,000 Peptidic Compounds with Covalent Warheads
- Gregoire Menoud - Senior PhD student, EPFL
08:35 - 09:0530 mins
Oligonucleotide Discovery, Preclinical and Clinical
siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism
- Shanthi Ganesh - Director, Novo Nordisk
08:35 - 09:0530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Perspectives and Learnings on Solvent Recovery in Oligonucleotide CMC
08:35 - 09:0530 mins
Peptide Discovery to CMC
Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition
- Ammar Ahmed, PhD - Senior Scientist, Chemical Development, AstraZeneca
09:05 - 09:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Peptide-Targeted Delivery of Oligonucleotide Therapeutics
- Hannah Bolt, PhD, MBA - Head of Peptide Discovery, AstraZeneca
09:05 - 09:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Rethinking Green Credentials for Oligo Manufacturing
- Louis Diorazio, PhD - Senior Principal Scientist, New Modalities, AstraZeneca
09:05 - 09:3530 mins
Peptide Discovery to CMC
Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme
- Louise Thorstholm - Senior Analytical Project Manager, Novo Nordisk
09:35 - 10:1540 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Refreshment Break in Poster and Exhibit Hall
10:15 - 10:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
PEP-NP : Peptide Based Nanoparticle-platform for Targeted Delivery of Functional RNAs
- Gilles Divita - Founder and CEO, Divincell
10:15 - 10:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Late Breaking Presentation
10:15 - 10:4530 mins
Peptide Discovery to CMC
Sustainability in Peptide Manufacturing
- Fernando Albericio, Ph.D - Research Professor, University of Kwazulu-Natal
10:45 - 11:1530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Intranasal Delivery of ASO/siRNA to the Brain
- Fabio Macciardi, MD, PhD - Chief Scientific Officer, Cognigenics
10:45 - 11:1530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Late Breaking Presentation
10:45 - 11:1530 mins
Peptide Discovery to CMC
MCSGP Process Control and Characterization Strategy
- Martina Niess - Scientist, F. Hoffmann-La Roche Ltd
11:15 - 11:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
xPhore: A Platform for DeLivering Therapeutic Nucleic Acids
- Covadonga Paneda, PhD - Chief Development Officer, Altamira Therapeutics
11:15 - 11:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Panel Discussion
11:15 - 11:4530 mins
Peptide Discovery to CMC
Late Breaking Presentation
11:45 - 11:505 mins
Transition to Spotlight Presentations
Spotlight Presentations
11:50 - 12:2030 mins
Spotlight Presentation 1
Peptide Diversity and Therapeutics by NMR: Scalable Methods from Early Sequences to Drug Candidates
- Shubhadra Pillay, PhD - Solutions Product Manager, Bruker BioSpin
11:50 - 12:2030 mins
Spotlight Presentation 2
GLP-1 Receptor Agonist Purification Combining Polymeric and Silica Reverse Phase Media
- Sophie Corbet - Bioprocessing Technical Service Manager, DuPont
12:20 - 13:2565 mins
Networking Luncheon in Poster and Exhibit Hall
Networking Luncheon in Poster and Exhibit Hall
Spotlight Presentations
13:55 - 14:005 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman's Remarks: Oligonucleotide Preclinical and Clinical Updates
13:55 - 14:005 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairman's Remarks: Analytical and CMC Strategies for Oligonucleotides
13:55 - 14:005 mins
Peptide Discovery to CMC
Chairman’s Remarks: Peptide Preclinical and Clinical
- Mimoun Ayoub, PhD - Senior VP, Global Head of Peptide and Oligonucleotide Platforms, CordenPharma International
14:00 - 14:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
FiCAT: Precise Gene Writing System for Next-generation CAR-T Cell Therapy Production
- Margot Pont, PhD - VP Translational Development, Integra Therapeutics
14:00 - 14:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Neutral Backbones and Dendrons for Enhanced Therapeutic Oligonucleotides Delivery
- Afaf El-Sagheer, PhD - Assistant Professor, University of Southampton
14:00 - 14:3030 mins
Peptide Discovery to CMC
Voxvoganan - A First in Class Mimetic of Antimicrobial Peptides
- John-Sigurd Svendsen, PhD - Founder and Chief Scientific Officer, Amicoat
14:30 - 15:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Targeting miRNAs for Disease Modification in Multifactorial CNS Disorders
- Lluís Riera-Ponsatí, PhD - Director of Preclinical Development, Neumirna Therapeutics
14:30 - 15:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development
- Joanna Hemming Taylor, PhD - Associate Principal Scientist, AstraZeneca
14:30 - 15:0030 mins
Peptide Discovery to CMC
Bicyclic Peptide Technology: Pioneering Next-Generation Precision-Guided Therapeutics
- Mark Frigerio - Vice President, Head of Platform Technology & Science, Bicycle Therapeutics
15:00 - 15:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Oligonucleotide Therapeutic Program Update
- Paul Nioi, PhD - SVP, Alnylam Pharmaceuticals, Inc.
15:00 - 15:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Synthesis and Characterization of Stereopure Chimeric Oligonucleotides
- Stephany Standley - Vice President, Oligonucleotide Synthesis and Chemistry, Wave Life Sciences
15:00 - 15:3030 mins
Peptide Discovery to CMC
Targeting Neurodegenerative Diseases with Priavoid’s Peptide Drug Development Platform
- Mathias Wendt, PhD - Senior Peptide Chemist, Priavoid GmbH
15:30 - 16:0030 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Refreshment Break in Poster and Exhibit Hall
16:00 - 16:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Beyond Silencing: ASOs as Protein Upregulators
- Nenad Svrzikapa, DPhil - Co-Founder, Head of Oligonucleotide Platform, Orfonyx Bio
16:00 - 16:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Late Breaking Presentation
16:00 - 16:3030 mins
Peptide Discovery to CMC
Oral GLP-1 Clinical Program or Amylin Phase 2 Program Update
- Kieren Mather, MD - Associate VP-Medical-Incretins and Diabetes Breakthroughs, Early Clinical Research, Eli Lilly and Company
16:30 - 17:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Interim Pharmacokinetic and Pharmacodynamic Results of the Phase 1/2a AVANCE1 Trial on Tricyclo-DNA-Induced DMD Exon 51 Skipping in Duchenne Muscular Dystrophy
- Luis Garcia - Président, SQY Therapeutics
16:30 - 17:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Late Breaking Presentation
16:30 - 17:0030 mins
Peptide Discovery to CMC
Next Generation Oncolytic Peptides - Drivers of Immunogenic Cell Death for Host Immune Activation
- Mark Eccleston - CEO, ValiRx
17:00 - 17:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
17:00 - 17:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Late Breaking Presentation
17:00 - 17:3030 mins
Peptide Discovery to CMC
Late Breaking Presentation
17:30 - 17:355 mins
Close of Conference - See You Next Year!
* 活动内容有可能不事先告知作更动及调整。